Skip to content
28 articles

Sciences

Life sciences, biotech, and research innovation.

Create content from your team’s expertise with free recording and AI writing tools. Qualifying companies also get one professional video edit a month. No credit card.

Chalmers' AI scientist turned 60,000 yeast records into nearly 2,000 testable ideas
Featured

Chalmers' AI scientist turned 60,000 yeast records into nearly 2,000 testable ideas

Eve, a robot scientist at Chalmers, generated hypotheses, designed yeast experiments and revised its own ideas. Lab data readiness is the real test.

MarketScale Newsroom·

All Articles

Why a 1% auto-injector change still means redoing most of the work

Why shared auto-injectors keep forcing rebuilt device files

Vertex Knight's Fubin Wu says a shared auto-injector forces rebuilt design files; ISPE says no platform device pathway exists yet.

MarketScale Newsroom·
Hepalink's FOYA-winning syringe plant inspects 24,000 units an hour

Hepalink's FOYA-winning syringe plant inspects 24,000 units an hour

Hepalink's Pingshan plant pairs sub-10 ms 5G, zero-touch AGVs and AI inspection to fill 330 million enoxaparin syringes a year on a land-scarce Shenzhen site.

MarketScale Newsroom·
Verdel's Q-2DMS aims to bring 2D mass spectrometry to more common hardware

Verdel's Q-2DMS aims to bring 2D mass spectrometry to more common hardware

Verdel and Warwick's Q-2DMS method reports up to tenfold more usable data on near-isobaric compounds, aiming to widen access to 2D mass spectrometry.

MarketScale Newsroom·
Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

FairJourney Bio's Maria Gonzalez-Pajuelo says developability has become a much more important consideration during antibody discovery.

MarketScale Newsroom·
AI shows up in all five tracks at ISPE's 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting chairs explain why AI has no track of its own—and why they expect it to show up across the five tracks, from discovery to governance.

MarketScale Newsroom·
Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego CRO designs preclinical oncology models to match specific therapies, including orthotopic brain tumors and post-treatment PDX…

Crown Bioscience·
Clinical data harmonization is the bottleneck for life sciences AI

Clinical data harmonization is the bottleneck for life sciences AI

Commentary argues life sciences AI hinges on clean, harmonized trial data that’s ready for machine learning pipelines—not just better models.

MarketScale Newsroom·
CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

BDO’s bioTRAK data shows CDMOs plan about 120 new bioreactors by 2030: 71% of added liters are large-scale stainless steel, but 61% of systems are single-use.

MarketScale Newsroom·
Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues pharma supply maps must cover airports, sea lanes and carriers, since suppliers in different countries can share one hub.

MarketScale Newsroom·
Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are expanding their strategic partnership, which began in 2023, with a series of substantial investments aimed at bolstering U.S. pharmaceutical manufacturing. The collaboration, marked by a $750 million investment, focuses on increasing the production of Lilly’s KwikPen®, a

Catherine Hanley·
ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

A 35-day AI run at ENEOS’ Yokkaichi butadiene unit is becoming the autonomy benchmark. The hard part now is data plumbing, governance, and where agents fit.

MarketScale Newsroom·
Novaspace sees 6,500+ Earth observation satellites by 2035, and the bottleneck moves to payloads

Novaspace sees 6,500+ Earth observation satellites by 2035, and value shifts to payload integration

Novaspace projects 6,500+ EO satellites through 2035 and $155.9B in manufacturing revenue. For operators, standard buses and multi-sensor payloads shift risk to

MarketScale Newsroom·
Samsung Biologics signs $262M manufacturing deal through 2033, pushing longer CDMO bookings

Samsung Biologics reports $262M manufacturing deal running through 2033

Samsung Biologics disclosed a $262 million manufacturing deal with an undisclosed European pharmaceutical company that runs through 2033.

MarketScale Newsroom·
Robotic Systems Emerge for Cell and Gene Therapy Manufacturing

Robotic Systems Emerge for Cell and Gene Therapy Manufacturing

A 2024 Cytotherapy study describes a robotic cluster built to automate manual cell therapy manufacturing steps.

MarketScale Newsroom·
Deloitte's Biopharma AI Value Estimates Come With a Timing Catch

Deloitte's Biopharma AI Value Estimates Come With a Timing Catch

Deloitte estimated top biopharma firms could capture $5-7B in AI value. McKinsey and ISPE material show why timelines and validation still lag.

MarketScale Newsroom·
CPC Biotech, Multiply Labs Develop Robot-Ready Cell Therapy Connector

CPC Biotech, Multiply Labs Develop Robot-Ready Cell Therapy Connector

CPC Biotech and Multiply Labs announced a robot-optimized aseptic connector for closed cell therapy manufacturing systems.

MarketScale Newsroom·
Lab automation ROI hinges on integration, not instrument sensitivity claims

Lab automation ROI hinges on integration, not instrument sensitivity claims

Waters’ “5x greater sensitivity” claim and LabCollector’s ELN/LIMS AI Co-Scientist point to the same constraint in lab automation: the handoffs, instrument to m

MarketScale Newsroom·
AeroVironment is building three Mars helicopters, and the supply chain looks like defense

AeroVironment to co-design three autonomous helicopters for NASA's SkyFall Mars mission

AeroVironment’s MacCready Works won work on three autonomous Mars helicopters for NASA’s SkyFall, putting aerospace-grade autonomy, avionics integration, and re

MarketScale Newsroom·
Telehealth "digital waiting rooms" are turning into premium pharma ad slots

Telehealth "digital waiting rooms" are turning into premium pharma ad slots

New patient-attention data and agency execution details are pushing pharma media plans toward pre- and post-visit virtual care moments.

MarketScale Newsroom·
Roche pTau217 clearance and Labcorp’s Alzheimer’s test bring diagnostics to primary care

Roche pTau217 clearance and Labcorp’s Alzheimer’s test bring diagnostics to primary care

New Alzheimer’s pathology tests and lab automation are shifting the bottleneck from assay availability to workflow activation.

MarketScale Newsroom·
Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031

Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031

Genentech will spend $750 million on a Hillsboro device fill-finish plant for prefilled syringes and autoinjectors, targeting commercial operations in 2031 and creating 250 manufacturing jobs.

MarketScale Newsroom·
4basebio hpDNA in Genezen projects could cut AAV input DNA by 30%

4basebio hpDNA in Genezen projects could cut AAV input DNA by 30%

Genezen will offer 4basebio’s cell-free hpDNA as starting material for viral vectors, a shift that could change how programs specify plasmids, timelines, and CO

MarketScale Newsroom·
Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers ended its deal with Cellares, a reminder that cell therapy supply plans still hinge on process fit, not just factory slots.

MarketScale Newsroom·
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation

From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Payerwatch·
What Exactly Is a 5-Log Reduction, and Why Does It Matter for Cleanroom Teams

What Exactly Is a 5-Log Reduction, and Why Does It Matter for Cleanroom Teams

In cleanroom environments, contamination control isn’t about vague cleanliness—it’s about measurable reductions, and a 5-log reduction means cutting microbial presence by 99.999%, turning 100,000 bacteria into just one. For cleanroom teams, this level of performance before disinfectants are even applied is critical, because it dramatically lowers bioburden risk and strengthens the effectiveness of every…

William Sepsis·
My Biggest Takeaway from NC State’s Bioprocessing Course

My Biggest Takeaway from NC State’s Bioprocessing Course

Hands-on immersion has become a defining advantage in modern biomanufacturing, and programs like NC State’s BTEC exemplify why experiential learning matters as much as technical knowledge. By stepping through a full upstream and downstream bioprocess in a simulated environment, the Benchmark team gained firsthand insight into the real-world pressures, decisions, and constraints their customers…

Mary Kate Campbell·
Lamar IoT’s Cutting-Edge Tracking Tech Prevents Drugs & High-End Food Products from Perishing

Lamar IoT’s Cutting-Edge Tracking Tech Prevents Drugs & High-End Food Products from Perishing

Real-time condition monitoring prevents costly losses of temperature-sensitive pharmaceuticals and perishables across complex global supply chains

Mike Bush·

From the archive

New to MarketScale?

MarketScale is the B2B media platform Sciences companies use to publish their own experts. Create a free workspace with no credit card, or book a demo to see how it works for your team.